Compare BBY & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBY | MDGL |
|---|---|---|
| Founded | 1966 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 12.2B |
| IPO Year | 1994 | 2005 |
| Metric | BBY | MDGL |
|---|---|---|
| Price | $66.76 | $520.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 12 |
| Target Price | $76.28 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 3.7M | 351.2K |
| Earning Date | 05-28-2026 | 04-28-2026 |
| Dividend Yield | ★ 5.74% | N/A |
| EPS Growth | 17.76 | ★ 41.32 |
| EPS | ★ 5.04 | N/A |
| Revenue | ★ $41,691,000,000.00 | $180,133,000.00 |
| Revenue This Year | $1.15 | $58.39 |
| Revenue Next Year | $1.38 | $48.55 |
| P/E Ratio | $13.33 | ★ N/A |
| Revenue Growth | ★ 0.39 | N/A |
| 52 Week Low | $59.77 | $265.00 |
| 52 Week High | $84.99 | $615.00 |
| Indicator | BBY | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 63.78 | 55.63 |
| Support Level | $66.21 | $503.93 |
| Resistance Level | $69.26 | $539.17 |
| Average True Range (ATR) | 1.87 | 17.10 |
| MACD | 0.53 | -1.58 |
| Stochastic Oscillator | 98.53 | 30.14 |
With over $41 billion in consolidated 2024 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8% share of the North American market and around 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.